Highlights

gloveharicut

Author: gloveharicut   |   Latest post: Mon, 19 Oct 2020, 9:26 AM

 

TOPGLOVE Q3 Slide - ALL GLOVE SHAREHOLDER MUST READ (1) 36% capacity growth (2) Monthly ASP revision (3) Higher % spot sales (4) Sales to DOUBLE Q4

Author:   |    Publish date:


TOPGLOVE is expecting more spectacular performance in coming quarters

 

During today webinar, Tan Sri Lim share this information.

  1. Top Glove Corporation Bhd expects better earnings in its current year ending 2020 (FY20) backed by the recent rise in ad hoc and spot orders by government agencies and global market demand. 
  2. It sales would likely double in its current fourth quarter, driven by higher average selling prices (ASP).
  3. It is now guiding for a monthly double-digit ASP increase at least for the next few months.
  4. Top Glove envisions "extremely" robust quarters ahead, driven by strong demand growth, high utilisation and additional capacity coming onstream.
  5. Following the increase in glove demand from virtually every country in the world, the group's utilisation rate rose from a pre-Covid level of 85 per cent to above 95 per cent in Q3.
  6. Demand backed by increased usage in both the medical and non-medical sectors, as well as heightened hygiene awareness
 
 




Share this
Labels: TOPGLOV

Related Stocks

Chart Stock Name Last Change Volume 
TOPGLOV 9.57 -0.03 (0.31%) 13,576,900 

  360Capitalist likes this.
 
gloveharicut During today webinar, Tan Sri Lim share this information.

Top Glove Corporation Bhd expects better earnings in its current year ending 2020 (FY20) backed by the recent rise in ad hoc and spot orders by government agencies and global market demand.
It sales would likely double in its current fourth quarter, driven by higher average selling prices (ASP).
It is now guiding for a monthly double-digit ASP increase at least for the next few months.
Top Glove envisions "extremely" robust quarters ahead, driven by strong demand growth, high utilisation and additional capacity coming onstream.
Following the increase in glove demand from virtually every country in the world, the group's utilisation rate rose from a pre-Covid level of 85 per cent to above 95 per cent in Q3.
Demand backed by increased usage in both the medical and non-medical sectors, as well as heightened hygiene awareness
11/06/2020 9:13 PM
Effendy Tay 10 cts for 17 k???
11/06/2020 9:22 PM
EngineeringProfit if 1.00 dividend plus bonus share, how to collect back the tickets from all the aunties and uncles?
11/06/2020 9:24 PM
CCCL If full year earning at 80 cents, with 50% pay out on dividen policy. At current rm17k per share, The dividen yield slightly better than bank 2% interest..
11/06/2020 9:54 PM


APPS
I3 Messenger
Individual or Group chat with anyone on I3investor
MQ Trader
Perform Technical & Fundamental Analysis on Stocks
MQ Affiliate
Earn rewards by referring your friends
 
 

282  407  581  1161 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 LUSTER 0.25+0.025 
 LAMBO 0.0350.00 
 MAHSING 1.36+0.12 
 KTB 0.17+0.055 
 XOX 0.1250.00 
 LUSTER-WA 0.155+0.025 
 MLAB 0.03-0.005 
 AT 0.100.00 
 PHB 0.025+0.005 
 SALCON-WB 0.145+0.015 

FEATURED POSTS

1. The Equity Market Index Benchmark in Malaysia CMS
2. Trading Scenarios of Derivatives Bursa Derivatives Education Series
3. Derivatives 101 Bursa Derivatives Education Series
4. Why Trade FKLI? Bursa Derivatives Education Series
5. MQ Trader - Introduction to MQ Trader Affiliate Program MQ Trader Announcement!

TOP ARTICLES

1. DON'T FORGET TO WATCH THIS EXPLOSYF COUNTER CLOSELY !!! Bursa Master
2. IT'S A TIME FOR THIS GLOVES GOING TO SKYROCKET!!! Follow Kim's Stockwatch!
3. A ZOOM Meeting With My Uncle (Retired Fund Manager) Learn from my Uncle (Retired Fund Manager)
4. PublicInvest Research Daily - 19 October 2020 PublicInvest Research
5. LET'S GET ROLLING THIS GLOVES TO NEXT LEVEL!!! Follow Kim's Stockwatch!
6. SUPERMAX - BEYOND GLOVES !!! freetospeak
7. Covid 19 cases in Malaysia - Koon Yew Yin Koon Yew Yin's Blog
8. LUSTER - IS IT ANOTHER GLOVE TITAN? HIDDEN WINNER(S) OF PHARMACEUTICAL DEMAND PENT UP
PARTNERS & BROKERS